Skip to main content
SLU publication database (SLUpub)

Abstract

Objective To determine the clinical efficacy and safety of a cremophor-free formulation of paclitaxel (Paccal Vet, Oasmia Pharmaceuticals) in dogs with mast cell tumours. Methods Paccal Vet was administered at a median dose of 145 (range, 135 to 150) mg/m2intravenously once every 21 days for three cycles to 29 dogs with macroscopic grade 2 or 3 mast cell tumour. Efficacy was assessed by tumour response (Response Evaluation Criteria in Solid Tumours version 1.0) and performance status score. Progression-free survival, quality of life and safety/adverse events were also evaluated. Clinical safety was assessed by clinicopathological analyses and recording of adverse events. Results Complete or partial response was observed in 59% of dogs. Performance status score remained constant or improved for 20 dogs and decreased by one grade for 9 dogs. Median time to progression was 247 (range, 42 to 268) days. Expected, transient frequently subclinical adverse events (primarily grade 3/4 neutropenia and grade 1/2 leukopenia) were observed in the majority of dogs. Nine dogs were euthanased and one dog died due to disease progression. Clinical Significance Paccal Vet appears to be a clinically safe and effective treatment for canine mast cell tumours. Further controlled confirmatory investigation is warranted.

Published in

Journal of Small Animal Practice
2013, volume: 54, number: 1, pages: 20-27
Publisher: WILEY-BLACKWELL

SLU Authors

UKÄ Subject classification

Clinical Science

Publication identifier

  • DOI: https://doi.org/10.1111/j.1748-5827.2012.01304.x

Permanent link to this page (URI)

https://res.slu.se/id/publ/52271